Tecan's OEM partner Dako unveils new platform at global congress

Tecan's OEM partner Dako unveils new platform at global congress 
MANNEDORF, SWITZERLAND -- (Marketwire) -- 03/07/13 --  Tecan Group AG
/ Tecan's OEM partner Dako unveils new platform at global congress .
Processed and transmitted by Thomson Reuters ONE. The issuer is
solely responsible for the content of this announcement. 
The Tecan Group (SIX Swiss Exchange: TECN) announced today that its
OEM partner Dako, an Agilent Technologies Company
and worldwide
provider of cancer diagnostics, unveiled the new advanced
platform at the 2013 USCAP congress in Baltimore, Maryland,
USA. Earlier this
week, it was presented to a global gathering of
pathologists and lab personnel
for the first time. 
In May 2011, Tecan signed a major OEM agreement with Dako for the
and supply of an advanced staining platform. Formerly the
development program
was referred to by Tecan as P16. The solution,
Dako Omnis, comprises hardware,
software and reagents. 
Lars Holmkvist, CEO of Dako said: "The Dako Omnis offers
full-automation to satisfy the needs of large-scale laboratories,
hospitals and universities. Tecan
has been our ideal development
partner for this system due to their strong application know-how and
experience with end-customer workflows in the IHC and
ISH segment.
Furthermore, as we progressed through the development, we found
Tecan shared our values of innovation and ownership and that their
experience in system integration was key in bringing the Dako OMNIS
to market." 
Tecan CEO David Martyr commented: "We are delighted to work with
Dako, a global
leader in the fast growing area of tissue-based cancer
diagnostics. The Dako
Omnis is really setting a new standard for
advanced staining. We expect sales
volumes for Tecan from the supply
of the Dako Omnis to accelerate from the second half of this year
with a substantial contribution to our sales growth
from 2014
onwards. Based on our partnership today, we look forward to
intensify our relationship with Dako in the future." 
Methods used in the diagnosis of abnormal cells such as those found
in cancerous
tumors include immunohistochemistry (IHC) and in situ
hybridization (ISH). The
Dako Omnis automates both IHC and ISH
processes, meaning entire patient cases
can be processed
simultaneously. This allows pathologists to make quicker,
informed diagnoses. Oncologists can in turn prescribe relevant
therapy with less
anxiety-ridden waiting time for patients. 
With continuous loading, batch loading and overnight run options all
Dako Omnis sets new standards for what customers can
expect from an automated
platform in terms of flexibility, capacity,
efficiency and traceability of slides. The platform provides
state-of-the-art software to bring lab control to a new level. Now,
key processes such as slide processing and instrument maintenance can
be traced to individual operators, greatly increasing
About Tecan 
Tecan (www.tecan.com) is a leading global provider of laboratory
instruments and solutions in biopharmaceuticals, forensics and
clinical diagnostics. The company
specializes in the development,
production and distribution of automated workflow solutions for
laboratories in the life sciences sector. Its clients
pharmaceutical and biotechnology companies, university research
departments, forensic and diagnostic laboratories. As an original
equipment manufacturer (OEM), Tecan is also a leader in developing and
manufacturing OEM
instruments and components that are then distributed
by partner companies. Founded in Switzerland in 1980, the company has
manufacturing, research and development sites in both Europe and
North America and maintains a sales and
service network in 52
countries. In 2012, Tecan generated sales of CHF 391 million (USD 416
million; EUR 323 million). Registered shares of Tecan
Group are
traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191). 
Press Release (PDF): http://hugin.info/100384/R/1683394/550922.pdf 
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants
(i) the releases contained herein are protected by copyright and    
other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and     
originality of the information contained therein. 
Source: Tecan Group AG via Thomson Reuters ONE 
For further information:
Tecan Group
Martin Braendle
Head of Corporate Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
Press spacebar to pause and continue. Press esc to stop.